What Вирфотен Treats: Main Uses and Benefits

The therapeutic application of Вирфотен (Tenofovir Disoproxil Fumarate) is primarily used in the long-term management and prevention of specific, persistent viral infections, and provides supportive relief that may help mitigate chronic disease progression.

The medication is commonly used across conditions presenting with chronic viral activity and applied across domains where additional symptomatic support is needed to achieve stability.

Therapeutic Contexts and Patient Support

This medication plays an important role as a component of treatment for conditions involving systemic viral imbalance, specifically: Human Immunodeficiency Virus (HIV) infection, Chronic Hepatitis B Virus (HBV) infection, and HIV Pre-Exposure Prophylaxis (PrEP).

For patients managing HIV, the primary therapeutic benefit is the preservation of immune function, which helps prevent the progressive decline in CD4 cell counts and may assist with reducing the risk of severe infections and illnesses. This contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress. In the context of HBV, the medication is applied to treat individuals where the condition involves active viral replication and inflammatory or irritative processes in the liver. By continuously suppressing the viral load, the medication offers the key benefit of minimizing active liver damage, supporting the long-term functional stability of the organ.

Quick Fact: Support for Chronic Viral Conditions

The medication supports patients by focusing on the underlying viral cause of chronic disease, rather than providing only temporary relief for localized symptoms. In a distinct preventative use, this medicine is also commonly used as part of PrEP for uninfected individuals at substantial risk of acquiring HIV-1. The benefit in this scenario generally helps reduce the overall risk of viral acquisition, which may assist with maintaining functional stability.

The eligibility for using Вирфотен (Tenofovir Disoproxil Fumarate) is strictly defined by regulatory documents based on patient population, age, and physiological status.

Populations for Whom Use is Contraindicated

Use is contraindicated in any patient with a documented hypersensitivity to the active substance or any of the inactive components of the formulation.

Eligibility Restricted by Organ Function and Age

The most significant limitation is tied to renal function. Use is not recommended in patients with severe renal impairment (Creatinine Clearance < 30 mL/min). For those with mild renal impairment, use is allowed but requires routine monitoring of kidney function. The medicine is generally approved for adults and for specific pediatric patients ge 2 years of age weighing at least 10 kg, with specific thresholds varying by indication. Use is not established in children younger than two years. Older adults (ge 65 years) may use the medicine but require caution due to the higher likelihood of decreased kidney function.

Pregnancy and Lactation Eligibility Status

Use during pregnancy is generally considered acceptable and is not contraindicated. However, for mothers with HIV, breastfeeding is not recommended due to the documented risk of postnatal viral transmission to the infant.

The official regulatory interaction profile for Вирфотен (Tenofovir Disoproxil Fumarate) establishes specific restrictions and monitoring requirements. Co-administration is formally prohibited with other tenofovir-containing products and with Adefovir Dipivoxil, a mandated restriction to mitigate the risk of drug accumulation and enhanced systemic toxicity.

Pharmacokinetic and Pharmacodynamic Interactions

The profile details additive toxicity concerns with concurrent use of nephrotoxic drugs, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Aminoglycosides, which increases the documented risk of renal impairment. Tenofovir is eliminated primarily via renal tubular secretion; therefore, co-administration with agents that compete for this OAT transporter pathway may lead to increased serum tenofovir concentrations.

Significant pharmacokinetic interactions are documented with agents that modify exposure. Co-administration with ritonavir- or cobicistat-boosted protease inhibitors increases tenofovir plasma concentrations, while co-administration with Didanosine (ddI) results in increased plasma concentrations of ddI. For physical restrictions, the regulatory label requires Activated Charcoal to be administered at least four hours apart from Вирфотен to ensure proper absorption. The clinical relevance of exposure-modifying interactions is heightened in patients with moderate to severe renal impairment.

The mechanism of action for Вирфотен (Tenofovir Disoproxil Fumarate) is initiated by its conversion inside host cells into the active metabolite, Tenofovir diphosphate (TFV-DP). This activation process prepares the molecule for its specific interference with viral replication. TFV-DP acts as a nucleotide analog, engaging in competitive inhibition against natural DNA precursors for binding at the active sites of essential viral enzymes: Reverse Transcriptase (in HIV) and DNA Polymerase (in HBV). The definitive molecular event occurs upon the incorporation of TFV-DP into the nascent viral DNA strand. Due to the lack of a 3′-hydroxyl group on the incorporated analog, the polymerization reaction is immediately and irreversibly terminated. This chain termination breaks the viral genetic synthesis pathway, leading to the suppression of systemic viral proliferation. The mechanism exhibits selective targeting, maintaining a far greater affinity for the viral enzymes than for human cellular DNA polymerases. However, the action is constrained by the emergence of specific resistance mutations (e.g., K65R) that reduce the viral enzyme’s sensitivity to TFV-DP.

How to Use Вирфотен

Вирфотен (Tenofovir Disoproxil Fumarate or TDF) administration is governed by specific instructions detailing the route, frequency, and dose adjustments required for proper use.

Official Administration Guidelines

Procedural Context and Adjustments

Official instructions mandate that the film-coated tablets be swallowed whole and not crushed. The medication is consistently taken once daily (QD). For adult patients with moderate to severe renal impairment, the standard 300 mg dose is maintained, but the dosing interval must be prolonged (e.g., every 48 hours for certain creatinine clearance thresholds) to prevent accumulation. This procedural adjustment, which changes the frequency rather than the dose strength, is critical for use in this population. The long-term pattern of use is typically continuous for sustained viral suppression.

Research evidence / Overview of Studies for Вирфотен

Evidence for Use in Treating HIV-1 Infection

Research exploring the use of Вирфотен in managing Human Immunodeficiency Virus Type 1 (HIV-1) infection was evaluated in large-scale Randomized Controlled Trials (RCTs). These studies typically involved administering the medicine as part of a combination regimen. Studies monitored changes in plasma HIV-1 RNA (viral load) and CD4 cells (immune markers). Findings showed patterns related to viral load suppression and changes in CD4 cell counts when the medicine was included in combination regimens. This evidence contributed to the broader evidence landscape.

Evidence for Use in Treating Chronic Hepatitis B

For chronic Hepatitis B Virus (HBV) infection, research has explored the medicine's role through pivotal RCTs. Studies monitored outcomes linked to inflammatory states in the liver by examining HBV DNA levels and Alanine Aminotransferase (ALT) levels. Findings describe patterns observed in the studies related to suppression of HBV DNA and changes in ALT levels in many observed populations. This evidence suggests patterns related to viral control and contributed to the broader evidence landscape related to chronic HBV.

Evidence for Use in HIV Prevention (Pre-Exposure Prophylaxis)

The role of this medicine in preventing HIV-1 infection (PrEP) was evaluated in large-scale placebo-controlled trials. Researchers focused on HIV-uninfected individuals at substantial risk. The main outcome examined was the incidence of new HIV-1 infections (seroconversion). Research describes patterns observed where groups taking the medicine reported differences in the rate of HIV acquisition compared to those on placebo. Research suggests patterns related to patient adherence in some studies.

Long-Term Studies and Follow-Up Data

Core clinical evidence is based on research evaluated over intermediate-term periods, typically ranging from 48 weeks to two years. Long-term open-label extension studies have been conducted, sometimes reaching up to seven years of continuous use. Despite this, certainty remains low regarding long-term outcomes, and research is ongoing to fully characterize the sustained effects.

Evidence in Special Study Populations

Research was conducted to evaluate the medicine in children and adolescents, as well as in adults co-infected with both HIV and HBV. Studies reported measurements of viral load and immune cell markers in these special populations. Comparative evidence is lacking for the optimal use in older adults, and subgroup findings are uncertain for pregnant or breastfeeding individuals.

What is Still Uncertain About the Research

Key limitations include the fact that results apply only to the populations studied and may not perfectly translate to every individual. Another key area of uncertainty is the precise optimal duration of treatment necessary for Chronic Hepatitis B; it is not yet clear whether studies have provided a clear cut-off for therapy.

Key Studies & References Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men (The iPrEx Trial)

Common questions about Вирфотен (FAQ)

Q: What are the early signs that my kidneys are being harmed by this medicine?

Official safety information indicates that Вирфотен carries a risk of kidney issues. Signs of potential severe kidney problems can include changes in your urination, such as increased or decreased frequency, and swelling of the legs and feet.

For a severe condition affecting the kidneys (Fanconi syndrome), symptoms that have been reported include bone pain or muscle weakness. Official guidance requires monitoring of kidney function before and during the use of this medication.

Q: If I’m HIV-positive, is it safe for me to breastfeed while on Вирфотен?

Official product information confirms that Tenofovir is detected in breast milk in small amounts. For mothers with HIV infection, regulatory guidance advises against breastfeeding to help avoid the risk of postnatal HIV transmission to the infant.

Q: Are there any physical restrictions, like driving or operating machinery, while on this medication?

Official documents list dizziness as a potential common side effect of Вирфотен. Because of this, patients are advised to note how the medicine affects them before deciding to drive or operate machinery.

Q: Does taking this drug cause changes in body weight or appetite?

Official patient drug information lists decreased appetite and loss of appetite as potential, though less common, side effects.

How to Store and Dispose of Вирфотен (Tenofovir Disoproxil Fumarate)

The official labeling mandates specific storage conditions to maintain the medicine's stability.

Storage Requirements

Stability and Disposal

For the oral granules, the contents must be used within 90 days after the bottle is opened. Unused or expired medication should be disposed of via a medicine take-back program. It is explicitly required that the product not be flushed down the toilet or poured into any drain.